Transcept Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference

The presentation will be available as a webcast at http://www.wsw.com/webcast/jeff26/transcept.

About Transcept Pharmaceuticals

Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company deriving significant new patient benefits from proven CNS drugs. Transcept development projects leverage new understanding of CNS conditions to provide additional uses and enhanced clinical benefits for existing active agents. The lead Transcept product candidate, Intermezzo(R) (zolpidem tartrate sublingual lozenge), is a low dose formulation of zolpidem for the treatment of insomnia in patients who awaken in the middle of the night and have difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and Transcept plans to submit an NDA in the third quarter of 2008. Transcept is also developing TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for the treatment of dopamine associated psychiatric disorders. For further information, please visit the company's website at: www.transcept.com.

    Contacts:

    Transcept Pharmaceuticals, Inc.           The Ruth Group
    Michael Gill                              Investors/Media
    Director of Communications                Stephanie Carrington/Jason Rando
    (510) 215-3575                            (646) 536-7017 / 7025
    mgill@transcept.com                       scarrington@theruthgroup.com
                                              jrando@theruthgroup.com

SOURCE Transcept Pharmaceuticals, Inc.